Parnax LAB Ltd.

NSE: PARNAXLAB · Pharmaceuticals · sector

₹103.35NSE close 2026-10-26

Key numbers

Market cap₹119 cr

Price₹103.35

52w high / low₹150 / ₹102

P/E13.3xSector median 27.9x

P/B1.2xSector median 2.9x

Book value₹82.8

Dividend yield–Sector median 0.48%

ROE10.0%Sector median 11.7%

ROCE10.7%Sector median 12.3%

OPM9.0%Sector median 14.0%

Debt / equity0.78xSector median 0.16x

EV/EBITDA8.4xSector median 18.6x

Interest cover3.0x

Current ratio0.95x

Sales growth 3y+221.6%Sector median +9.6%

Profit growth 3y+113.5%Sector median +13.3%

PEG0.12x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹2 cr vs borrowings ₹75 cr (FY26): borrowings are higher by ₹72 cr.
Operating profit covered interest 3.0x in the last 12 months.
Other income was 42% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹103.35 on 2026-10-26: -30.9% from the 52-week high, +1.3% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹178.10 · low ₹84.04

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	49	53	63	63	70	57
EBITDA	7	7	8	6	5	4
OPM %	13.5%	13.9%	12.9%	9.1%	6.7%	7.6%
Other income	0	0	1	1	2	0
Net profit	3	3	4	3	2	0
EPS (₹)	2.55	2.85	3.15	2.37	1.90	0.37
Revenue YoY					+42.0%	+6.4%
Profit YoY					-25.3%	-86.9%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	7	7	7	188	249	252
EBITDA	1	2	2	27	26	23
Net profit	1	1	2	12	12	9
EPS (₹)	0.64	1.09	1.59	10.05	10.27	7.79
Revenue growth		+4.5%	-0.4%	+2,423.4%	+32.4%	–
Profit growth		+124.1%	+50.4%	+533.0%	+2.3%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+221.6%	–	–
Net profit	+113.5%	–	–
EPS	+111.2%	–	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	83	95
Borrowings	61	75
Cash & equivalents	3	2
Total assets	190	228
Fixed assets	109	114
Capital work in progress	1	11
Investments	0	0
Receivables	31	38
Inventory	26	36
Payables	21	32

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	32	8
Cash from investing	-16	-16
Cash from financing	-16	8
Capex	19	17
Free cash flow	14	-9

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	13.9%	12.4%
ROCE %	14.7%	12.7%
Debtor days	60	56
Inventory days	98	90
Payable days	81	80
Cash conversion cycle (days)	77	66
Working capital days	-19	-8

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
PARNAXLAB	₹119 cr	13.3x	1.2x	10.0%	10.7%	9.0%	+221.6%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	PARNAXLAB
BSE code	506128
ISIN	INE383L01019
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.